Investment-Ready Through Rigorous Valuation and Due Diligence

At Maravion, we help deep-tech, biotech, pharmaceutical, and innovation-driven companies become investment-ready through rigorous valuation, techno-economic analysis, and commercial due diligence. In highly technical sectors where businesses are often built around intellectual property, scientific know-how, and emerging technologies, investors require more than promising research. They need confidence that the innovation can scale commercially, navigate regulatory pathways, and generate long-term value.

One of Maravion’s core service areas is supporting startups, scale-ups, and innovation-driven organisations with detailed company valuations and techno-economic assessments. These exercises are essential for informing equity negotiations, structuring funding rounds, supporting licensing discussions, and positioning companies for commercial growth. Our approach combines scientific, technical, market, and financial analysis to provide a realistic understanding of both opportunity and risk.

In deep-tech and biotech sectors, company value is rarely determined by revenue alone. Instead, value is often linked to intellectual property strength, technology readiness, scalability, manufacturing feasibility, regulatory positioning, and competitive differentiation. Maravion therefore evaluates a broad range of commercial and operational factors, including forecasted market potential, R&D pipeline viability, scale-up costs, capital infrastructure requirements, and long-term commercial sustainability.

To support these assessments, we develop robust financial models that include discounted cash flow analysis, internal rate of return calculations, net present value modelling, return on investment scenarios, and sensitivity analysis. These models help founders, investors, and funders better understand capital requirements, growth potential, and the key assumptions driving business value. In sectors characterised by long development timelines and high technical uncertainty, this level of analysis is critical for informed decision-making.

Maravion has supported companies in securing investment rounds ranging from approximately R10 million to more than US$10 million. These investments have supported activities such as product development, GMP scale-up studies, regulatory preparation, manufacturing feasibility assessments, and early commercialisation activities. While many of these engagements remain confidential under non-disclosure agreements, they reflect our extensive experience working within the biotech, pharmaceutical, health technology, and broader deep-tech sectors.

Beyond private sector engagements, Maravion also supports public sector institutions, funding agencies, and innovation ecosystem partners through commercial and technical due diligence exercises. These assessments are essential for de-risking public investment into innovation and ensuring alignment with broader industrial and national development priorities. Our due diligence process typically evaluates intellectual property position and freedom-to-operate, business model viability, regulatory pathway feasibility, scalability, manufacturing readiness, strategic partnership opportunities, and market access potential.

Our experience has consistently shown that successful deep-tech ventures require more than breakthrough science. They require commercial clarity, financial discipline, and a credible pathway to scale. Investors and funders are increasingly seeking businesses that not only possess strong technology, but also demonstrate a realistic understanding of market dynamics, capital requirements, operational risks, and long-term sustainability.

At Maravion, our goal is to help innovators build credible, investable businesses capable of attracting funding, forming strategic partnerships, and scaling sustainably. Whether supporting a startup preparing for its first investment round, a university spinout commercialising new intellectual property, or a biotech company expanding into manufacturing and regional markets, we provide the strategic, technical, and financial expertise needed to support growth.

Because in deep-tech and biotechnology, successful innovation is not only about scientific excellence. It is about transforming science into commercially viable businesses that can deliver lasting economic and societal impact.

Rigorous Valuation and Due Diligence